Kate Simpson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kate Simpson has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Johannes Steffen Kern
Monash University - Clayton Campus, Clayton, Victoria, Australia
2 shared publications Alicia Snowden
Epworth Healthcare East Melbourne Victoria Australia
1 shared publicationAnne Howard
Dermatology Department The Royal Melbourne Hospital Parkville Victoria Australia
1 shared publicationChris McCormack
Department of Surgical Oncology Peter MacCallum Cancer Centre Parkville Victoria Australia
1 shared publicationCon Dolianitis
University of Melbourne Parkville Victoria Australia
1 shared publicationDaniel Kidd
Department of Pathology The Royal Melbourne Hospital Parkville Victoria Australia
1 shared publication
Latest Publications
- 26 May 2026
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (6) , 360-363
A Case of Primary Cutaneous BRAF V600E+ Langerhans Cell Histiocytosis, With Underlying Chronic Myelomonocytic Leukaemia, Responsive to Dabrafenib With Subsequent Undetectable Circulating Cell Free DNA
We present a case of BRAF V600E+ primary cutaneous Langerhan cell histiocytosis (LCH), with corresponding circulating cell free DNA (cfDNA), which responded to treatment with dabrafenib, and simultaneously saw corresponding BRAF V600E cfDNA become undetectable. A concomitant diagnosis of chronic myelomonocytic leukaemia (CMML) was suspected with identification of TP53 , TET2 , RAS and CBL variants identified through molecular testing on the initial skin biopsy, and CMML later confirmed on bone marrow biopsy. Whilst the link between LCH and several haematological malignancies is documented, the mechanism is still unclear. In this case, the LCH most likely developed from an already abnormal myeloid compartment and highlights the need for clinical vigilance and appropriate investigation, where effective treatments for these conditions exist.
- 26 May 2026
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (6) , 360-363
A Case of Primary Cutaneous BRAF V600E+ Langerhans Cell Histiocytosis, With Underlying Chronic Myelomonocytic Leukaemia, Responsive to Dabrafenib With Subsequent Undetectable Circulating Cell Free DNA
We present a case of BRAF V600E+ primary cutaneous Langerhan cell histiocytosis (LCH), with corresponding circulating cell free DNA (cfDNA), which responded to treatment with dabrafenib, and simultaneously saw corresponding BRAF V600E cfDNA become undetectable. A concomitant diagnosis of chronic myelomonocytic leukaemia (CMML) was suspected with identification of TP53 , TET2 , RAS and CBL variants identified through molecular testing on the initial skin biopsy, and CMML later confirmed on bone marrow biopsy. Whilst the link between LCH and several haematological malignancies is documented, the mechanism is still unclear. In this case, the LCH most likely developed from an already abnormal myeloid compartment and highlights the need for clinical vigilance and appropriate investigation, where effective treatments for these conditions exist.
- 15 October 2021
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 186 (3) , 581-583
Ultralow‐dose rituximab in pemphigus: a single‐centre experience
- 15 October 2021
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 186 (3) , 581-583
Ultralow‐dose rituximab in pemphigus: a single‐centre experience
- 11 June 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (3) , 390-393
Successful management of treatment resistant nail psoriasis with tildrakizumab
Nail psoriasis significantly impacts quality of life and is notoriously difficult to treat. Tildrakizumab, an IL‐23 inhibitor, has shown significant clinical improvement in the treatment of moderate‐to‐severe chronic plaque psoriasis. We report 2 cases of treatment resistant nail psoriasis which showed marked improvement with the use of off‐label tildrakizumab. The dosing regimen utilised was consistent with that used to treat chronic plaque psoriasis, with 100 mg subcutaneously at Day 0 and Week 4, and maintenance dosing of 100 mg every 12 weeks thereafter. Significant improvement at 6 and 12 months, as per the modified Nail Psoriasis Severity Index (mNAPSI) and Dermatology Life Quality Index (DLQI), was seen. There have been no tildrakizumab related side effects observed to date. Tildrakizumab appears to be an effective option in managing treatment resistant nail psoriasis.
- 11 June 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (3) , 390-393
Successful management of treatment resistant nail psoriasis with tildrakizumab
Nail psoriasis significantly impacts quality of life and is notoriously difficult to treat. Tildrakizumab, an IL‐23 inhibitor, has shown significant clinical improvement in the treatment of moderate‐to‐severe chronic plaque psoriasis. We report 2 cases of treatment resistant nail psoriasis which showed marked improvement with the use of off‐label tildrakizumab. The dosing regimen utilised was consistent with that used to treat chronic plaque psoriasis, with 100 mg subcutaneously at Day 0 and Week 4, and maintenance dosing of 100 mg every 12 weeks thereafter. Significant improvement at 6 and 12 months, as per the modified Nail Psoriasis Severity Index (mNAPSI) and Dermatology Life Quality Index (DLQI), was seen. There have been no tildrakizumab related side effects observed to date. Tildrakizumab appears to be an effective option in managing treatment resistant nail psoriasis.
- 26 May 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (3) , 314-322
Comparison of the EUROIMMUN Dermatology Profile ELISA to the novel BIOCHIP Mosaic 7 for the diagnosis of immunobullous skin disease
Background: The BIOCHIP is an indirect immunofluorescence diagnostic investigation which identifies multiple autoantibodies with a mosaic panel of target antigen‐specific substrates in a single incubation field. The EUROIMMUN Dermatology Profile ELISA allows simultaneous investigation of the six most important autoantibodies in bullous autoimmune dermatoses. Evaluation of the BIOCHIP Mosaic 7, compared to that of the EUROIMMUN Dermatology Profile ELISA, when used as a diagnostic investigation in pemphigus and pemphigoid, was undertaken in an Australian cohort.Methods: The serum of 27 patients was analysed including patients with pemphigus vulgaris (n = 10), pemphigus foliaceous (n = 4), bullous pemphigoid (n = 8), mucous membrane pemphigoid (n = 3) and negative controls (n = 2). Results of the BIOCHIP were compared with the EUROIMMUN Dermatology Profile ELISA, as well as with histology, direct immunofluorescence and indirect immunofluorescence.Results: In pemphigus vulgaris, sensitivity & specificity for the BIOCHIP Mosaic 7 were 100% and 94.1%, comparable to that of the EUROIMMUN Dermatology Profile ELISA with 80% sensitivity and 100% specificity. In bullous pemphigoid, sensitivity of the BIOCHIP was 87.5% and sensitivity of the EUROIMMUN Dermatology ELISA profile was 75%, whilst specificities for both diagnostic methods were 100% in our limited cohort. There was substantial or almost perfect concordance between the BIOCHIP Mosaic 7 and EUROIMMUN Dermatology Profile ELISA for pemphigus vulgaris and bullous pemphigoid.Conclusion: The BIOCHIP Mosaic 7 is a rapid, reliable diagnostic investigation in pemphigus and bullous pemphigoid. Results indicate it is comparable to the EUROIMMUN Dermatology Profile ELISA, whilst also providing additional testing with salt split skin, on one field.
- 26 May 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (3) , 314-322
Comparison of the EUROIMMUN Dermatology Profile ELISA to the novel BIOCHIP Mosaic 7 for the diagnosis of immunobullous skin disease
Background: The BIOCHIP is an indirect immunofluorescence diagnostic investigation which identifies multiple autoantibodies with a mosaic panel of target antigen‐specific substrates in a single incubation field. The EUROIMMUN Dermatology Profile ELISA allows simultaneous investigation of the six most important autoantibodies in bullous autoimmune dermatoses. Evaluation of the BIOCHIP Mosaic 7, compared to that of the EUROIMMUN Dermatology Profile ELISA, when used as a diagnostic investigation in pemphigus and pemphigoid, was undertaken in an Australian cohort.Methods: The serum of 27 patients was analysed including patients with pemphigus vulgaris (n = 10), pemphigus foliaceous (n = 4), bullous pemphigoid (n = 8), mucous membrane pemphigoid (n = 3) and negative controls (n = 2). Results of the BIOCHIP were compared with the EUROIMMUN Dermatology Profile ELISA, as well as with histology, direct immunofluorescence and indirect immunofluorescence.Results: In pemphigus vulgaris, sensitivity & specificity for the BIOCHIP Mosaic 7 were 100% and 94.1%, comparable to that of the EUROIMMUN Dermatology Profile ELISA with 80% sensitivity and 100% specificity. In bullous pemphigoid, sensitivity of the BIOCHIP was 87.5% and sensitivity of the EUROIMMUN Dermatology ELISA profile was 75%, whilst specificities for both diagnostic methods were 100% in our limited cohort. There was substantial or almost perfect concordance between the BIOCHIP Mosaic 7 and EUROIMMUN Dermatology Profile ELISA for pemphigus vulgaris and bullous pemphigoid.Conclusion: The BIOCHIP Mosaic 7 is a rapid, reliable diagnostic investigation in pemphigus and bullous pemphigoid. Results indicate it is comparable to the EUROIMMUN Dermatology Profile ELISA, whilst also providing additional testing with salt split skin, on one field.
- 24 May 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (3) , 441-442
A case of treatment‐resistant pityriasis rubra pilaris responsive to secukinumab
- 24 May 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (3) , 441-442
A case of treatment‐resistant pityriasis rubra pilaris responsive to secukinumab